We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Read MoreHide Full Article
Aurinia Pharmaceuticals (AUPH - Free Report) shares rallied 5.6% in the last trading session to close at $5.65. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.
The sudden soar in the stock price of the company is likely due to the positive momentum built around its pipeline. Aurinia's sole-marketed product, Lupkynis, is approved in the United States for the treatment of lupus nephritis. The product has witnessed solid uptake since its launch and is expected to perform well in the quarters ahead. Additionally, the company is also exploring alternative approaches for its pre-clinical candidate, AUR200.
This biotechnology company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +112.5%. Revenues are expected to be $54.89 million, up 32.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aurinia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUPH going forward to see if this recent jump can turn into more strength down the road.
Aurinia is part of the Zacks Medical - Drugs industry. Esperion Therapeutics (ESPR - Free Report) , another stock in the same industry, closed the last trading session 2.8% higher at $2.99. ESPR has returned 12.4% in the past month.
For Esperion Therapeutics, the consensus EPS estimate for the upcoming report has changed +1.8% over the past month to -$0.18. This represents a change of +60.9% from what the company reported a year ago. Esperion Therapeutics currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Aurinia Pharmaceuticals (AUPH - Free Report) shares rallied 5.6% in the last trading session to close at $5.65. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.
The sudden soar in the stock price of the company is likely due to the positive momentum built around its pipeline. Aurinia's sole-marketed product, Lupkynis, is approved in the United States for the treatment of lupus nephritis. The product has witnessed solid uptake since its launch and is expected to perform well in the quarters ahead. Additionally, the company is also exploring alternative approaches for its pre-clinical candidate, AUR200.
This biotechnology company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +112.5%. Revenues are expected to be $54.89 million, up 32.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aurinia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUPH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Aurinia is part of the Zacks Medical - Drugs industry. Esperion Therapeutics (ESPR - Free Report) , another stock in the same industry, closed the last trading session 2.8% higher at $2.99. ESPR has returned 12.4% in the past month.
For Esperion Therapeutics, the consensus EPS estimate for the upcoming report has changed +1.8% over the past month to -$0.18. This represents a change of +60.9% from what the company reported a year ago. Esperion Therapeutics currently has a Zacks Rank of #3 (Hold).